Literature DB >> 8851463

Evaluation of the financial impact of ketorolac tromethamine therapy in hospitalized patients.

J P Burke1, S L Pestotnik, D C Classen, J F Lloyd.   

Abstract

This retrospective cohort study aimed to determine the resource utilization and cost consequences of ketorolac tromethamine in postoperative pain management in a variety of clinical circumstances. All patients were treated at LDS Hospital, Salt Lake City, Utah, a 520-bed teaching hospital. A long-term archive of clinical and financial data from a computerized hospital information system was searched for patients with specified primary International Classification of Diseases, 9th Revision, Clinical Modification discharge diagnoses treated from June 1, 1990, to July 1, 1992, who received ketorolac (n = 229). These patients were matched with cohort patients (n = 821) treated from July 1, 1989, to May 31, 1990, who did not receive ketorolac. The archive contained information on ketorolac exposure as well as concurrent drug therapy and adverse drug events that had been prospectively evaluated during hospitalization throughout the study and cohort periods. Detailed costs were available for each patient. The study examined attributable differences in lengths of stay and total costs using linear regression modeling. We found a statistically significant attributable decreased length of stay for ketorolac patients of 1.15 days. Case patients also had reduced usage of narcotic drugs (4.39 fewer doses than cohorts and 15.6 hours shorter duration of narcotics than cohorts), reduced use of antiemetic and antipruritic medications, and reduced numbers of adverse events. Linear regression modeling showed that ketorolac use was significantly related to reduced cost using inflation-adjusted dollars. We believe that ketorolac has significant cost advantages over opiate analgesics because of its narcotic-sparing effects. Advantages of ketorolac use include reduced rates of adverse drug events, reduced lengths of stay, especially for orthopedic surgery, and reduced overall hospital costs for diagnosis-related groups associated with cholecystectomy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8851463     DOI: 10.1016/s0149-2918(96)80190-1

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  6 in total

Review 1.  Ketorolac. A reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic use in pain management.

Authors:  J C Gillis; R N Brogden
Journal:  Drugs       Date:  1997-01       Impact factor: 9.546

Review 2.  Ketorolac for postoperative pain management in children.

Authors:  J B Forrest; E L Heitlinger; S Revell
Journal:  Drug Saf       Date:  1997-05       Impact factor: 5.606

3.  Cost effectiveness analysis of intravenous ketorolac and morphine for treating pain after limb injury: double blind randomised controlled trial.

Authors:  T H Rainer; P Jacobs; Y C Ng; N K Cheung; M Tam; P K Lam; R Wong; R A Cocks
Journal:  BMJ       Date:  2000-11-18

Review 4.  Reduction of breast cancer relapses with perioperative non-steroidal anti-inflammatory drugs: new findings and a review.

Authors:  Michael Retsky; Romano Demicheli; William J M Hrushesky; Patrice Forget; Marc De Kock; Isaac Gukas; Rick A Rogers; Michael Baum; Vikas Sukhatme; Jayant S Vaidya
Journal:  Curr Med Chem       Date:  2013       Impact factor: 4.530

Review 5.  Breast cancer and the black swan.

Authors:  Michael Retsky; Romano Demicheli; William Hrushesky; Ted James; Rick Rogers; Michael Baum; Jayant S Vaidya; Osaro Erhabor; Patrice Forget
Journal:  Ecancermedicalscience       Date:  2020-05-28

6.  Promising development from translational or perhaps anti-translational research in breast cancer.

Authors:  Michael Retsky; Romano Demicheli; William Jm Hrushesky; Patrice Forget; Marc De Kock; Isaac Gukas; Rick A Rogers; Michael Baum; Katharine Pachmann; Jayant S Vaidya
Journal:  Clin Transl Med       Date:  2012-08-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.